> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biokin collects a second $250 million BMS milestone for iza-bren, bringing cash receipts to $1.3 billion
- URL: https://chinapharmadesk.com/biokin-systimmune-bms-izabren-second-250m-milestone/
- Published: 2026-11-19T02:47:21.000Z
- Updated: 2026-11-19T03:24:48.000Z
- Description: Sichuan Biokin (SSE: 688506) disclosed in filing No. 2026-089 that SystImmune received a second $250 million BMS milestone for EGFRxHER3 ADC iza-bren (BL-B01D1), lifting total cash collected to $1.3 billion.
- Author: Lin Yi
- Tags: Desk brief, Deals & BD, Capital, Oncology & ADC

[Sichuan Biokin Pharmaceutical Co., Ltd.](https://static.cninfo.com.cn/finalpage/2026-11-18/1225676544.PDF?ref=chinapharmadesk.com) (`Baili-Bio`, SSE: 688506) announced in Shanghai Stock Exchange filing No. 2026-089 on November 18, 2026 that its wholly owned U.S. subsidiary `SystImmune, Inc.` has received a second $250 million milestone payment (less bank charges) from Bristol Myers Squibb (`NYSE: BMY`) under their December 2023 global strategic collaboration on the `EGFR×HER3` bispecific antibody-drug conjugate `izalontamab brengitecan` (`iza-bren` / `BL-B01D1`, marketed in China as `Yizekang`). Combined with the $800 million upfront payment collected in March 2024 and the first $250 million milestone received in December 2025, Biokin has now banked $1.3 billion in cash under the up-to-$8.4 billion agreement, with up to $7.1 billion in additional development, regulatory and sales milestones still contingent.

## The `IZABRIGHT-Lung02` trigger and the six-month lag from expectation to cash

While filing No. 2026-089 confirms cash receipt, cross-referencing Biokin’s [September 22, 2026 trigger announcement (No. 2026-068)](https://static.cninfo.com.cn/finalpage/2026-09-22/1225575603.PDF?ref=chinapharmadesk.com) and its [Q3 2026 financial report](https://static.cninfo.com.cn/finalpage/2026-10-31/1225650264.PDF?ref=chinapharmadesk.com) (filed October 31, 2026) documents the clinical event and accounting timeline behind the payment:

| Tranche under Dec 11, 2023 BMS Agreement (No. 2023-057) | Gross Amount           | Clinical / Contractual Trigger                                                                                                                                             | Trigger Disclosure           | Cash Receipt Date                    |
| ------------------------------------------------------- | ---------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------- | ------------------------------------ |
| **Upfront payment** (non-refundable, non-creditable)    | **$800 million**       | Agreement effectiveness & global co-development launch                                                                                                                     | Dec 12, 2023 (No. 2023-057)  | March 2024                           |
| **First near-term contingent milestone**                | **$250 million**       | Global Phase 2/3 IZABRIGHT-Breast01 ([NCT06926868](https://clinicaltrials.gov/study/NCT06926868?ref=chinapharmadesk.com)) reaching prespecified milestone on Sept 30, 2025 | Oct 2025                     | December 2025 (No. 2025-088)         |
| **Second near-term contingent milestone**               | **$250 million**       | Global Phase 3 **IZABRIGHT-Lung02** ([NCT06838273](https://clinicaltrials.gov/study/NCT06838273?ref=chinapharmadesk.com)) reaching prespecified milestone in Sept 2026     | Sept 22, 2026 (No. 2026-068) | **November 18, 2026 (No. 2026-089)** |
| **Remaining contingent milestones**                     | **Up to $7.1 billion** | Specified future development, regulatory and commercial sales thresholds (plus tiered royalties ex-U.S. and U.S. profit/loss share)                                        | Contingent                   | Unfulfilled                          |

`IZABRIGHT-Lung02` (`NCT06838273`) is a global Phase 3 trial enrolling roughly 850 patients with first-line `EGFR`\-mutated (`Ex19del` or `L858R`) locally advanced or metastatic non-small cell lung cancer (`NSCLC`), evaluating `iza-bren` in combination with `osimertinib` against `osimertinib` monotherapy or `osimertinib` plus platinum-pemetrexed chemotherapy. In May 2026, Biokin told investors on the SSE interactive platform that the second clinical milestone under the BMS agreement had not yet been met, illustrating how milestone cash inflows depend on global enrollment and protocol gates even while domestic R&D burn runs continuously.

## Why the $250 million cash arrival matters to Biokin’s Q3 balance sheet

Biokin’s Q3 2026 financial statements show that the company had already accrued the second $250 million milestone as revenue in the third quarter when `IZABRIGHT-Lung02` hit its trigger in September, creating a temporary working-capital gap that November’s cash wire now closes:

1. **Accrued Q3 profit vs. nine-month cash burn**: Recognizing the milestone drove Biokin’s Q3 2026 revenue to **RMB 1.907 billion (approx. $263.8 million)** and Q3 net profit attributable to shareholders to **RMB 932.3 million (approx. $129.0 million)**. However, because the cash had not yet arrived by September 30, accounts receivable surged from RMB 68.0 million at year-end 2025 to **RMB 1.767 billion (approx. $244.4 million)** on September 30, 2026, while operating cash flow remained negative at **\-RMB 632.0 million** for Q3 and **\-RMB 2.168 billion (approx. -$300.0 million)** for the first nine months of 2026.
2. **A 113% R&D-to-revenue ratio across 45+ clinical trials**: Across the first nine months of 2026, Biokin’s total R&D investment jumped 33.54% year-on-year to **RMB 2.367 billion (approx. $327.4 million)**—equal to **113.03% of its RMB 2.094 billion nine-month revenue** (expensed R&D was RMB 2.045 billion, or 97.69% of revenue, with RMB 321.3 million capitalized as development expenditure). That clinical spend left Biokin with a nine-month net loss of **RMB 704.9 million** (deducted non-GAAP net loss of **RMB 770.5 million**).
3. **Liquidity and leverage**: As of September 30, 2026, before the $250 million (approx. RMB 1.80 billion) wire cleared in November, Biokin held **RMB 4.514 billion** in cash and bank balances plus **RMB 1.917 billion** in trading financial assets (totaling RMB 6.432 billion, or approx. $889.6 million), offset by **RMB 5.230 billion** in long-term borrowings (up 99.93% from year-end 2025) and **RMB 1.267 billion** in short-term debt and current maturities.

## Domestic commercial ramp: two NMPA approvals and 2027 NRDL entry

With both $250 million near-term clinical milestones under the BMS pact now collected, Biokin’s next non-dilutive inflows shift toward domestic oncology sales and later-stage global registration triggers. In China, `iza-bren` (`Yizekang`) became the world’s first approved bispecific ADC when the NMPA granted conditional approval on June 22, 2026 for third-line or later recurrent or metastatic nasopharyngeal carcinoma (`NPC`), followed in July 2026 by a second approval in PD-1/PD-L1-experienced recurrent or metastatic esophageal squamous cell carcinoma (`ESCC`).

As detailed in our [2026 NRDL and Commercial List overhaul analysis](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/) and Biokin’s [November 16 SSE filing (1225672396.PDF)](https://static.cninfo.com.cn/finalpage/2026-11-16/1225672396.PDF?ref=chinapharmadesk.com), `iza-bren` was added on November 14, 2026 to China’s 2026 National Reimbursement Drug List (`NRDL`) for adult patients with recurrent or metastatic `NPC` who have failed at least two prior lines of systemic chemotherapy including a PD-1 or PD-L1 inhibitor, with national reimbursement taking effect from January 1, 2027 through December 31, 2028.

The next verifiable checkpoints for Biokin and `iza-bren` are provincial procurement (*guawang*) price postings for `Yizekang` ahead of the January 1, 2027 NRDL rollout; full-year 2026 operating cash flow and debt-to-cash balances after booking the November $250 million wire; and primary readouts from BMS and SystImmune’s global registrational trials—`IZABRIGHT-Breast01` (`NCT06926868`), `IZABRIGHT-Lung02` (`NCT06838273`), and `BL-M07D1` (`trastuzumab brengitecan`, `NCT07869836`).